Burjanadze Gia, Gorgodze Nikoloz, Aquaro Giovanni Donato, Gabisonia Khatia, Carlucci Lucia, Pachauri Manendra, Turreni Federico, Secco Ilaria, Bernini Fabio, Zentilin Lorena, Giacca Mauro, Recchia Fabio A
Interdisciplinary Research Center "Health Science," Scuola Superiore Sant'Anna, Pisa, Italy.
Aging + Cardiovascular Discovery Center, Lewis Katz School of Medicine, Philadelphia, Pennsylvania, USA.
JACC Basic Transl Sci. 2025 Feb 7;10(5):634-49. doi: 10.1016/j.jacbts.2024.12.014.
miR-199a carried by adeno-associated virus serotype 6 (AAV6) proved cardioreparative in a pig model when administered early after myocardial infarction (MI). To test whether the therapeutic efficacy of miR-199a is maintained when its administration is delayed, AAV6-miR-199a or a control AAV6 were injected 1 or 2 weeks after MI. Scar mass and cardiac contractile performance parameters were not significantly different between AAV6-miR-199a-treated and AAV6-control pigs. Nonetheless, most AAV6-miR-199a-treated pigs died from sudden death at 40 to 52 days after vector administration. For clinical translation, it appears mandatory to administer miR-199a early after MI and through modalities other than permanent expression from a viral vector.
在猪模型中,心肌梗死(MI)后早期给予由6型腺相关病毒(AAV6)携带的miR-199a可证实具有心脏修复作用。为了测试延迟给予miR-199a时其治疗效果是否能得以维持,在MI后1周或2周注射AAV6-miR-199a或对照AAV6。接受AAV6-miR-199a治疗的猪和接受AAV6对照的猪之间,瘢痕质量和心脏收缩性能参数并无显著差异。尽管如此,大多数接受AAV6-miR-199a治疗的猪在载体给药后40至52天死于猝死。对于临床转化而言,似乎必须在MI后早期通过非病毒载体永久表达以外的方式给予miR-199a。